AbL Diagnostics SA (ABLD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AbL Diagnostics SA (ABLD) has a cash flow conversion efficiency ratio of 0.069x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€479.46K ≈ $560.54K USD) by net assets (€6.93 Million ≈ $8.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ABLD net asset quality index to measure how much of total assets are equity-financed.
AbL Diagnostics SA - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how AbL Diagnostics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AbL Diagnostics SA (ABLD) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
AbL Diagnostics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AbL Diagnostics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WT Financial Group Ltd
AU:WTL
|
0.125x |
|
NOCTILUCA S.A. ZY -15
F:G0Z
|
-0.105x |
|
Massimo Group Common Stock
NASDAQ:MAMO
|
0.169x |
|
Farm Price Holdings Berhad
KLSE:0304
|
0.039x |
|
Casing Macron Technology Co Ltd
TWO:3325
|
0.026x |
|
Wisher Industrial Co Ltd
TW:1465
|
-0.178x |
|
Sprint Bioscience AB
ST:SPRINT
|
-0.182x |
|
Zegona Communications Plc
LSE:ZEG
|
0.120x |
Annual Cash Flow Conversion Efficiency for AbL Diagnostics SA (2017–2025)
The table below shows the annual cash flow conversion efficiency of AbL Diagnostics SA from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of AbL Diagnostics SA.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €7.63 Million ≈ $8.92 Million |
€1.51 Million ≈ $1.76 Million |
0.198x | +209.34% |
| 2024-12-31 | €7.49 Million ≈ $8.75 Million |
€-1.35 Million ≈ $-1.58 Million |
-0.181x | -231.96% |
| 2023-12-31 | €6.77 Million ≈ $7.91 Million |
€926.43K ≈ $1.08 Million |
0.137x | +1804.30% |
| 2022-12-31 | €6.75 Million ≈ $7.90 Million |
€-54.25K ≈ $-63.42K |
-0.008x | +62.89% |
| 2021-12-31 | €2.62 Million ≈ $3.06 Million |
€-56.69K ≈ $-66.28K |
-0.022x | -273.21% |
| 2020-12-31 | €2.36 Million ≈ $2.76 Million |
€29.51K ≈ $34.50K |
0.012x | +131.83% |
| 2019-12-31 | €7.09 Million ≈ $8.29 Million |
€-278.40K ≈ $-325.48K |
-0.039x | -446.32% |
| 2018-12-31 | €7.15 Million ≈ $8.36 Million |
€81.10K ≈ $94.82K |
0.011x | -87.62% |
| 2017-12-31 | €7.37 Million ≈ $8.62 Million |
€675.20K ≈ $789.38K |
0.092x | -- |
About AbL Diagnostics SA
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more